Fundraising FoxNorthpond Ventures — 2024 Investments
3 investments dated 2024 · listed companies and verified rows first · show all
Transition Bio applies methods from physics, chemistry, biology, and machine learning to study protein biophysics—including protein aggregation, self-assembly, and protein-protein interactions—for developing therapeutics targeting health and disease.
AI & Machine LearningBiotechDeep TechCambridge, US
Tuomas Knowles(Executive Director, Co-Founder & Chief Technology Officer)Samuel Cohen(Executive Director & Co-Founder)inG. Kelly Martin(Executive Chairman & Co-Founder)George Martin(Executive Officer, Director)inStephanie Torruella(Executive Officer)inPreet Makkar(Executive Officer)
Co-investorsLifeforce CapitalMagnetic VenturesTaiho Ventures, LLCDolby Family Ventures
Eleanor Health is an outpatient addiction treatment program that delivers remote evidence-based care for substance use disorder, including medication-assisted treatment and counseling.
Digital HealthHealthtechMental HealthWaltham, US
Dr. Nzinga Harrison(Chief Medical Officer and Co-founder)Corbin Petro(Executive Officer, Director)Srishti Mirchandani(Executive Officer)in
BoardDavid Whelan(Director)inSonny Goyal(Director)Kurt Sheline(Director)in
Co-investorsEcho Health VenturesGeneral CatalystRethink ImpactTown Hall VenturesWarburg Pincus
.png)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
W Labs
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.